Cargando…

Activation and lysis of human CD4 cells latently infected with HIV-1

The treatment of AIDS with combination antiretroviral therapy (cART) remains lifelong largely because the virus persists in latent reservoirs. Elimination of latently infected cells could therefore reduce treatment duration and facilitate immune reconstitution. Here we report an approach to reduce t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pegu, Amarendra, Asokan, Mangaiarkarasi, Wu, Lan, Wang, Keyun, Hataye, Jason, Casazza, Joseph P., Guo, Xiaoti, Shi, Wei, Georgiev, Ivelin, Zhou, Tongqing, Chen, Xuejun, O'Dell, Sijy, Todd, John-Paul, Kwong, Peter D., Rao, Srinivas S., Yang, Zhi-yong, Koup, Richard A., Mascola, John R., Nabel, Gary J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Pub. Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633990/ https://www.ncbi.nlm.nih.gov/pubmed/26485194 http://dx.doi.org/10.1038/ncomms9447

Ejemplares similares

Removal of variable domain N-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies
por: Chuang, Gwo-Yu, et al.
Publicado: (2020)

Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody
por: Kwon, Young D., et al.
Publicado: (2018)

Improvement of antibody functionality by structure-guided paratope engraftment
por: Liu, Qingbo, et al.
Publicado: (2019)

Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections
por: Promsote, Wanwisa, et al.
Publicado: (2023)

Partial germline reversions can increase VRC07 potency and breadth
por: Rudicell, RS, et al.
Publicado: (2012)

Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life
por: Zhang, Baoshan, et al.
Publicado: (2022)

A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention
por: Kwon, Young D., et al.
Publicado: (2021)

Structure-guided modification and optimization of antibody VRC07
por: Kwon, Y, et al.
Publicado: (2012)

Mammalian production of an isotopically enriched outer domain of the HIV-1 gp120 glycoprotein for NMR spectroscopy
por: Sastry, Mallika, et al.
Publicado: (2011)

Anti-viral efficacy of a next-generation CD4-binding site bNAb in SHIV-infected animals in the absence of anti-drug antibody responses
por: Lovelace, Sarah E., et al.
Publicado: (2022)

Primate immune responses to HIV-1 Env formulated in the saponin-based adjuvant AbISCO-100 in the presence or absence of TLR9 co-stimulation
por: Martinez, Paola, et al.
Publicado: (2015)

Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain
por: Kwon, Young D., et al.
Publicado: (2023)

Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base
por: Corrigan, Angela R., et al.
Publicado: (2021)

The changing face of HIV vaccine research
por: Kwong, Peter D, et al.
Publicado: (2012)

Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention
por: Kisalu, Neville K., et al.
Publicado: (2021)

Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates
por: Sundling, Christopher, et al.
Publicado: (2010)

Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates
por: Sundling, Christopher, et al.
Publicado: (2010)

Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors
por: González, Nuria, et al.
Publicado: (2018)

Improved delivery of broadly neutralizing antibodies by nanocapsules suppresses SHIV infection in the CNS of infant rhesus macaques
por: Wen, Jing, et al.
Publicado: (2021)

P13-01. Crystal structure and function of a monoclonal antibody against primate CD4 that blocks HIV/SIV infection
por: Pegu, A, et al.
Publicado: (2009)

Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability
por: Mason, Rosemarie D., et al.
Publicado: (2016)

Correction: Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability
por: Mason, Rosemarie D., et al.
Publicado: (2016)

Hyperglycosylated resurfaced stabilized GP120 core as an immunogen elicits antibodies targeted at the CD4-binding site
por: Dai, K, et al.
Publicado: (2012)

Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials
por: Huang, Yunda, et al.
Publicado: (2018)

Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency
por: Zhang, Baoshan, et al.
Publicado: (2023)

P09-05. Mechanism of HIV-1 resistance to a monoclonal antibody that effectively targets the site of CD4 attachment
por: Wu, X, et al.
Publicado: (2009)

NEP: web server for epitope prediction based on antibody neutralization of viral strains with diverse sequences
por: Chuang, Gwo-Yu, et al.
Publicado: (2014)

Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability
por: Shi, Wei, et al.
Publicado: (2022)

Delayed vaginal SHIV infection in VRC01 and anti-α4β7 treated rhesus macaques
por: Calenda, Giulia, et al.
Publicado: (2019)

Somatic Populations of PGT135–137 HIV-1-Neutralizing Antibodies Identified by 454 Pyrosequencing and Bioinformatics
por: Zhu, Jiang, et al.
Publicado: (2012)

Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability
por: Shi, Wei, et al.
Publicado: (2022)

Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site
por: Crooks, Ema T., et al.
Publicado: (2015)

Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting
por: Doria-Rose, Nicole A., et al.
Publicado: (2017)

Antibodyomics: bioinformatics technologies for understanding B‐cell immunity to HIV‐1
por: Kwong, Peter D., et al.
Publicado: (2017)

Transforming epitope-specific gp120 monomer-based probes into immunogens with N-linked glycan masking
por: Chuang, G, et al.
Publicado: (2012)

Structure-Based Stabilization of HIV-1 gp120 Enhances Humoral Immune Responses to the Induced Co-Receptor Binding Site
por: Dey, Barna, et al.
Publicado: (2009)

Characteristics of HIV-1 gp120 molecules that bind ancestor, intermediate and mature forms of VRC01-like antibodies
por: Joyce, M, et al.
Publicado: (2012)

Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1
por: Xu, Kai, et al.
Publicado: (2018)

TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption
por: Hsu, Denise C., et al.
Publicado: (2021)

Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery
por: Liu, Cuiping, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jjhkhjbdjiifp73asguvm3mler